MINNEAPOLIS, March 24, 2025 /PRNewswire/ — Ovative Group, a leading performance marketing and measurement firm, unveiled its highly anticipated 2025 EMR Power Rankings, providing marketers with essential data on which paid media channels drive the highest Enterprise Marketing Return (EMR). As brands navigate an increasingly omni-focused landscape, these rankings deliver actionable insights to optimize media investments and maximize business impact.

With the lines between ecommerce and in-store sales continuing to blur, Ovative’s proprietary EMR framework—powered by its EMRge™ technology—offers a holistic approach to measuring media’s full-funnel impact. Unlike traditional ROAS metrics, EMR accounts for online and offline revenue, future customer value, incrementality, and profitability, empowering marketers to make smarter, more sustainable media investment decisions.

“The 2025 EMR Power Rankings go beyond digital performance metrics to reveal the true impact of media on a brand’s bottom line,” said Alexander Matoushek, author of the EMR Power Rankings report. “This data is a game-changer for brands looking to maximize omni-channel profitability.”

Key Insights from the 2025 EMR Power Rankings:

TikTok: Despite regulatory uncertainty, TikTok surged in effectiveness, especially in driving in-store sales.Retail Media: Climbed from #15 to #8 in under nine months, proving its increasing value in the media mix.Connected TV (CTV): Dropped from #6 to #16 as audience fragmentation and saturation challenge its effectiveness.Upper Funnel Channels: TikTok, Meta, and audio saw increased impact on in-store sales, underscoring the importance of investing in top-of-funnel brand-building efforts.

How Brands Can Take Action

Marketers can leverage the 2025 EMR Power Rankings to determine which channels are right for their brand and partner with Ovative’s experts to craft a customized media strategy tailored to their business needs. Full rankings and insights can be accessed here.

About Ovative Group

Ovative Group is an independent, full-funnel media, measurement, and creative firm. Leveraging deep industry expertise, we help brands like Domino’s, Facebook, The Home Depot, General Mills, Disney, and UnitedHealth Group transform their media and measurement programs. The result? Profitable growth that speaks for itself.

At Ovative, we don’t just track data—we redefine success. How do we do it? Our proprietary MarTech platform, EMRge™, helps businesses transform marketing into a driver of sustainable growth. Powered by Enterprise Marketing Return (EMR), our differentiated approach to holistic media buying, planning, and measurement, EMRge™ is the first MarTech platform to measure businesses holistically. We raise the bar every day, and it shows. Our work has been recognized by organizations like Digiday, Google, Inc. 5000, USA Today, and Search Engine Land.

For more information about Ovative, visit our website or follow Ovative on Facebook, Instagram, LinkedIn, and Twitter.

Media Contact:
Jasmin Stevens
VP, Marketing
jasmin.stevens@ovative.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ovative-group-reveals-2025-emr-power-rankings-empowering-marketers-to-drive-omni-sales-impact-302409780.html

SOURCE Ovative Group

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity and aimed to expand its portfolio through in-licensing pharma innovation. With an increasing focus on patient-friendly drug administration, the company sought to in-license a dissolvable microneedle technology (dMTS)—a non-invasive platform capable of delivering a variety of drugs and vaccines through a patch format. However, the road to in-licensed products was not without hurdles.

LAS VEGAS, March 24, 2025 /PRNewswire/ — The objective was to assess dissolvable microneedle technology and identify top licensing partner companies with the right technological competencies, clinical capabilities, and commercial readiness using secondary and primary intelligence. The company needed a comprehensive pharma market assessment to evaluate potential partners developing innovative dMTS-based drug delivery systems, ensuring they had the expertise to bring novel concepts from the lab to clinical trials and, ultimately, the market.

Recognizing the situation’s complexity and the advantages of in-licensing and out-licensing, the company turned to DelveInsight, a trusted expert in pharma market intelligence and strategic licensing. Using a combination of secondary and primary intelligence, DelveInsight conducted a deep dive into the pharma in-licensing landscape, identifying the most promising players in the microneedle technology space. The assessment provided the company with a clear roadmap—pinpointing potential partners, evaluating their clinical pipelines, and determining their in-licensing agreement potential.

In the evolving pharmaceutical landscape, bridging the gap between scientific innovation and commercial success is a persistent challenge. Many blockbuster drugs and drug delivery technologies originate from smaller biotech firms or academic research centers, where groundbreaking discoveries happen, but commercial expertise is often lacking. This is where pharma in-licensing becomes a game-changer—allowing large players to acquire cutting-edge innovations and propel them toward clinical development and market success.

Looking for the right in-licensing opportunities? Reach out to us today! Get a tailored proposal and let DelveInsight guide you with expert market intelligence and strategic licensing support.

DelveInsight’s Methodology: A Strategic Approach to In-Licensing dMTS Technology

To help the company identify the right in-licensing opportunity in dissolvable microneedle technology (dMTS), DelveInsight applied a structured, intelligence-driven approach. By leveraging its expertise in pharma licensing services and conducting comprehensive assessments, DelveInsight provided actionable insights that enabled the company to make informed decisions for in-licensing pharma assets.

dMTS Market Assessment: DelveInsight conducted an in-depth pharma market assessment, analyzing the Asia-Pacific landscape for dissolvable microneedle technology and identifying growth trends, key players, and competitive positioning in the in-licensed products space.Company Assessment: DelveInsight evaluated potential licensing partners, assessing their technological capabilities, clinical progress, and commercial readiness to support a successful in-licensing agreement.Technology Assessment: A detailed review of R&D innovations, product pipelines, and formulation technology helped determine the feasibility of in-licensing drugs from top microneedle technology developers.Investment Assessment: DelveInsight analyzed funding patterns, partnerships, and acquisition trends within the dMTS sector, ensuring that potential pharma in-licensing partners had strong financial backing and a robust growth strategy.Primary Assessment: Using primary intelligence, DelveInsight conducted expert interviews, industry surveys, and KOL engagements, validating key findings and gaining deeper insights into the capabilities of potential partners.Strategic Insights on Companies: DelveInsight provided a detailed competitive analysis, highlighting the strengths, weaknesses, opportunities, and risks of various in-licensing opportunities to ensure the client partnered with the most viable company.Assessment of Own Company: By analyzing the client’s existing portfolio, commercial strengths, and expansion goals, DelveInsight identified gaps and strategic areas for growth, ensuring a strong alignment with the selected in-licensing and out-licensing in pharma opportunities.Strategic Goal Building: Finally, DelveInsight helped the company develop a clear roadmap for in-licensing success, outlining potential partnerships, deal structures, and commercialization strategies to drive clinical development and commercial milestone achievement.

Through this intelligence-backed methodology, DelveInsight provided the client with a data-driven, strategic approach to in-licensing, enabling them to secure the right licensing opportunity and expand their footprint in the drug delivery technology market.

Strategic Outcomes with DelveInsight’s Licensing Expertise:

Matrix Analysis identified and positioned the top 20 potential licensing partners based on their technological, clinical, and commercial capabilities.The client gained a clear assessment of the top companies best aligned with their strategic goals and licensing objectives (the TARGET quadrant).DelveInsight facilitated direct meetings with 4-5 high-potential companies, enabling the client to advance in-licensing discussions efficiently.

By leveraging DelveInsight’s expertise, the company successfully secured a high-value in-licensing opportunity, giving a scientific innovation the boost it needed to reach clinical development and commercial milestone achievement. This case underscores the benefits of in-licensing—a strategic approach that enables large pharmaceutical players to stay ahead of the competition by integrating cutting-edge research into their pipelines while ensuring that breakthrough therapies reach the market faster.

Exciting, isn’t it? Don’t just watch innovation happen—secure it! Explore top in-licensing opportunities with our expert guidance.

Regulatory Analysis: DelveInsight’s regulatory intelligence services simplify global approvals by consolidating complex regulatory data into a single platform. With ever-changing guidelines and country-specific requirements, navigating approvals for NCEs, biologics, biosimilars, and cell or gene therapies can be daunting. A single misstep can mean costly delays. Our experts provide clear, comparative insights into global regulatory frameworks, helping clients streamline approvals, mitigate risks, and prioritize markets with faster access.

Portfolio Management: DelveInsight’s Portfolio Management services help clients assess competencies, leverage strengths, and align strategic priorities. Our structured approach identifies market needs, optimizes resources, and enhances portfolio value. With comprehensive market intelligence, we empower organizations to make informed, data-driven decisions, minimizing risks and maximizing long-term impact for both customers and the company.

R&D Analysis: DelveInsight’s skilled research and development analyst specializes in the complexities of different indications, offering essential insights and advice to clients aiming to advance in research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each drug in both pre-clinical and clinical stages. DelveInsight’s comprehensive reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence.

Why Choose DelveInsight?

DelveInsight’s Licensing Services help pharma companies secure the best in-licensing and out-licensing opportunities by identifying strategic partners and facilitating successful deal-making. With expertise across all therapeutic areas and a vast global network, we provide comprehensive market intelligence, decision-mapping matrix assessments, and expert engagement services to streamline the licensing process. Our approach ensures that clients receive a curated list of potential partners, expert-led discussions, and in-depth strategic insights, making licensing decisions more effective and result-driven. In an industry where the right partnerships drive commercial success, DelveInsight’s systematic methodology ensures seamless negotiations and long-term growth.

Ready to find the perfect licensing partner? Let’s connect!

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/in-licensing-opportunity-how-a-pharma-leader-leveraged-scientific-innovation-for-clinical-and-commercial-success–delveinsight-302407772.html

LONDON, March 24, 2025 /PRNewswire/ — Dreame Technology is celebrating the season with an exciting Spring Sale, offering up to 25% off on its latest flagship smart home cleaning products.

From powerful robot vacuums to high-performance wet and dry vacuums, premium hair styling tools, and advanced robotic lawn mowers, now is the perfect time to upgrade your home with Dreame’s cutting-edge innovations.

X50 Ultra Complete: Rise Up, Clean Beneath

Available on Amazon & the Dreame Store

Original Price: £1,299Spring Sale Price: £1,099

Dreame’s most advanced robot vacuum, the X50 Ultra Complete, introduces a new level of home cleaning with its ProLeap™ System featuring 6cm obstacle-crossing ability. Its VersaLift Navigation allows the robot to lower itself to just 8.9cm for deep cleaning under furniture. The HyperStream™ Detangling DuoBrush System effectively captures and removes hair, while the 20,000Pa suction power ensures thorough dirt and debris removal.

H15 Pro Wet and Dry Vacuum: A Complete Clean, Untangled and Spotless

Available on Amazon & the Dreame Store

Original Price: £599Spring Sale Price: £499

The H15 Pro is the industry’s first wet and dry vacuum with an AI robotic arm, delivering GapFree™ triple-edge coverage to reach every corner. The TangleCut™ system ensures a tangle-free brush, while the Thermo Tub™ high-temp self-cleaning system provides effortless maintenance with 100°C hot water rinsing and high-speed drying.

Z30 Cordless Stick Vacuum: Unmatched Suction Power for Smarter Cleaning

Available on Amazon & the Dreame Store

Original Price: £399Spring Sale Price: £299

The Z30 redefines cleaning efficiency with 310AW of powerful suction*, the highest in Dreame’s cordless vacuum lineup. Its advanced brushless motor ensures exceptional debris removal, while a 99.99% filtration rate captures fine dust, bacteria, and allergens with a HEPA filter. Equipped with smart infrared sensors, the Z30 detects particles as small as 10µm, automatically adjusting suction power for optimized cleaning. The real-time LCD display provides instant feedback on cleaning performance, balancing power, battery efficiency, and runtime for a seamless, intelligent cleaning experience.

Limited-Time Savings from March 25 to March 31

The Dreame Spring Sale offers a unique opportunity to invest in state-of-the-art cleaning and styling innovations at exceptional prices. These exclusive discounts are available for a limited time on Dreame’s official website and Amazon store. Customers are encouraged to act quickly to secure the best deals before the promotion ends.

About Dreame Technology

Founded in 2017, Dreame Technology is a forward-thinking company committed to empowering users through innovative smart home solutions. By integrating cutting-edge technology—such as high-speed motors, machine vision, SLAM, and multi-cone cyclone separation—Dreame strives to make everyday tasks effortless and efficient. With over 150 core patents, Dreame offers a diverse range of products, including robot vacuums, wet and dry vacuums, cordless stick vacuums, lawn mowers, and hair care tools. Focused on enhancing quality of life, Dreame continues to redefine convenience and performance, helping users enjoy smarter, cleaner, and more empowered living every day.

Contact – Ranieri PR: dreame@ranieri.agency

Photo – https://mma.prnewswire.com/media/2648838/ProLeap_System_W6CM1.jpg
Photo – https://mma.prnewswire.com/media/2648839/Triple_Edge_Coverage.jpg
Photo – https://mma.prnewswire.com/media/2648840/Dreame_Z30_Cordless_Vac.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/spring-clean-smarter-with-dreame-enjoy-up-to-25-off-in-our-biggest-sale-of-the-season-302409789.html